Home LiteratureArticle Details
PMID: 19710641 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment.

Clinical pharmacology and therapeutics ·Vol. 86 ·No. 4 ·2009-10-00 ·Pages 438-41

Petersen RC, Jack CR

Abstract

A major focus of research on aging and dementia pertains to the prediction of future cognitive decline. Toward this end, several longitudinal studies are under way that are designed to explore early predictors of cognitive impairment. Neuroimaging techniques and biomarkers have shown promise in this application. Ultimately, it is likely that the use of a combination of neuroimaging and chemical biomarkers will be involved in predicting the development of dementia and Alzheimer's disease (AD).

MeSH Terms
Alzheimer Disease/diagnosis,diagnostic imaging,metabolism Aniline Compounds Biomarkers/analysis Brain/diagnostic imaging,metabolism Humans Magnetic Resonance Imaging Positron-Emission Tomography Thiazoles
Chemicals
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole Aniline Compounds Biomarkers Thiazoles
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Petersen R C
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. [email protected]
Jack C R
References (28)
28 references, click to expand
  1. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    Neurobiol Aging. 2006 Mar;27(3):394-401 PMID: 16125823
  2. Mild cognitive impairment.
    Lancet. 2006 Apr 15;367(9518):1262-70 PMID: 16631882
  3. Mild cognitive impairment as a diagnostic entity.
    J Intern Med. 2004 Sep;256(3):183-94 PMID: 15324362
  4. Functional magnetic resonance imaging changes in amnestic and nonamnestic mild cognitive impairment during encoding and recognition tasks.
    J Int Neuropsychol Soc. 2009 May;15(3):372-82 PMID: 19402923
  5. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
    Neurology. 2003 Apr 22;60(8):1374-7 PMID: 12707450
  6. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment.
    Neurology. 2005 Mar 8;64(5):902-4 PMID: 15753434
  7. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology. 2001 May 8;56(9):1143-53 PMID: 11342678
  8. Safety and efficacy of galantamine in subjects with mild cognitive impairment.
    Neurology. 2008 May 27;70(22):2024-35 PMID: 18322263
  9. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.
    Neurology. 1999 Apr 22;52(7):1397-403 PMID: 10227624
  10. Imaging beta-amyloid burden in aging and dementia.
    Neurology. 2007 May 15;68(20):1718-25 PMID: 17502554
  11. Asymmetric cortical degenerative syndromes: clinical and radiologic correlations.
    Neurology. 1992 Aug;42(8):1462-8 PMID: 1641136
  12. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
    Am J Public Health. 1998 Sep;88(9):1337-42 PMID: 9736873
  13. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  14. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  15. CSF markers for incipient Alzheimer's disease.
    Lancet Neurol. 2003 Oct;2(10):605-13 PMID: 14505582
  16. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease.
    J Magn Reson Imaging. 1997 Nov-Dec;7(6):1069-75 PMID: 9400851
  17. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):557-8 PMID: 11561022
  18. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  19. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Ann Neurol. 2009 Apr;65(4):403-13 PMID: 19296504
  20. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
    Neurology. 2010 Jan 19;74(3):201-9 PMID: 20042704
  21. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
    N Engl J Med. 1996 Mar 21;334(12):752-8 PMID: 8592548
  22. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Arch Gen Psychiatry. 2004 Jan;61(1):95-102 PMID: 14706948
  23. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances.
    Annu Rev Public Health. 2002;23:213-31 PMID: 11910061
  24. Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
    NeuroRx. 2004 Apr;1(2):213-25 PMID: 15717022
  25. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Brain. 2009 May;132(Pt 5):1355-65 PMID: 19339253
  26. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.
    Neurology. 1997 Dec;49(6):1513-21 PMID: 9409338
  27. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Arch Neurol. 2007 Mar;64(3):343-9 PMID: 17210801
  28. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
Article Info
Journal
Clinical pharmacology and therapeutics
Abbr.
Clin Pharmacol Ther
ISSN
1532-6535
DOI
10.1038/clpt.2009.166
Email
[email protected]
Published
2009-10-00
Epub
2009-00-26
Pages
438-41
Language
English
Region
United States
NLM ID
0372741
PMCID
PMC3098135
Subset
IM
Grants
NIA NIH HHS · P50 AG16574 · United States
NIA NIH HHS · U01 AG024904-01 · United States
NIA NIH HHS · R01 AG011378-12 · United States
NIA NIH HHS · R01 AG11378 · United States
NIA NIH HHS · P50 AG016574 · United States
NIA NIH HHS · P50 AG016574-10 · United States
NIA NIH HHS · U01 AG06786 · United States
NIA NIH HHS · U01 AG006786 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U01 AG006786-22 · United States
NIA NIH HHS · U19 AG010483 · United States
NIA NIH HHS · U01 AG24904 · United States
NIA NIH HHS · R01 AG011378 · United States
External Links
PubMed source DOI: 10.1038/clpt.2009.166 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2